

A Powerful Pairing for Wound and Amputation Prevention

Prosenex's DND has developed a new effective software partnership with TreVia Digital Health to screen for peripheral neuropathy.

By Michael W. Brown, President, Prosenex and Matt Dobski, VP Strategy & Business Development, TreVia Digital Health

Foot complications are now the most common and expensive diabetes-related cause of admittance to hospitals in most countries in the world, and amputations are among the most feared outcomes of diabetes. According to a report from the new global Guidance of the International Working Group on the Diabetic Foot (IWGDF), five key areas were identified: prevention, footwear and offloading, diagnosis and treatment of peripheral artery disease, infection and wound care.

The results provide demonstrable, objective documentation to support the new ADA standard of care.

Prevention begins with the diabetic foot exam. The cornerstone of the comprehensive foot assessment is objective peripheral neuropathy screening. Physicians are frequently frustrated with the inconsistency of available neurological screening examinations. The absence of subjective complaints and frequent late complications drove the need for an earliest possible objective screening method. The need to help a practitioner to overcome the deficiency and inconsistency of the screening foot



exam is paramount in patients with DPN.

Prosenex's Dynamic Neuroscreening Device (DND) provides for objective graded screening for peripheral neuropathy using temperature and vibration discrimination. The temperature feature assesses a patient's ability to discriminate temperature differences from 2 to 10 degrees C. This feature is best suited to assess small fiber vitality. The vibration feature, designed to assess large fiber vitality, emulates a standard tuning fork but provides quantitative results of the smallest vibration level that the patient can discriminate. The DND is compliant with the recommendation of the American Diabetes Association and goals of the Affordable Healthcare Act. Presently, there is no other handheld, portable neuropathy screening device for the diabetic foot offering graded temperature and vibration discrimination that is suitable for use in all clinical environments. It is designed to replace the current subjective methods of detecting neuropathy and introduce innovative, research-supported graded temperature discrimination for small fiber neuropathy.



The TreVia Platform Advantage:

TreVia is a health care company focused on enabling the new diabetes care ecosystem. TreVia provides technology-enabled services—including telemedicine, peripheral neuropathy screenings, and digital diabetic retinopathy—for the prevention and treatment of diabetic complications. Physicians, health care organizations, payers, retail clinics and patients use TreVia's holistic solutions and tools so they can provide simple preventative care where consumers/


Continued on page 132

Prosenex *(continued)*

patients find it convenient with a goal of achieving better outcomes and ensuring the consumer has an optimal experience and improved quality of life.

Prosenex and TreVia Partnership: A new standard of care for neuropathy screening.

Through a partnership with TreVia Digital Health, the objective, graded results are captured and stored for immediate evaluation, as well as for longitudinal evaluation and progression measures. This provides demonstrable, objective documentation to support the new ADA standard of care, which requires a peripheral exam at every appointment to measure progression and identify neurological issues to avoid limb loss. The Prosenex DND device provides a comprehensive foot exam in 3 to 5 minutes, and integrates with the TreVia software platform that delivers enhanced services, improved quality and elevated standard of peripheral neuropathy care.



Further benefits include:

- More responsive, higher quality & differentiated service for patients
- Shows longitudinal changes in patient's diabetic neuropathy health

- Improves compliance with medical advice by providing objective numerical data of the sensitivity status

- Handheld device is low profile, non-invasive and easy to administer

- Used in the office, home or where needed

- Care monitoring and alerts ensure compliance & follow-up care

The DND results are quantified by vibration & temperature and entered for each location. Each location includes Red/Yellow/Green severity visuals as shown in the screen shot. The powerful color coding system provides a quick visual assessment of the risk of DPN complications for the patient.

For more information call 603-546-0457, visit www.prosenex.com, www.treviadigitalhealth.com, or [click here](#).